文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

转移性胃癌PD-1抑制临床反应的全面分子特征

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
PubMed 文献 · Nat Med · 2018-07-16

该研究对61例接受帕博利珠单抗挽救治疗的转移性胃癌患者进行组织与循环肿瘤DNA分子特征分析。微卫星高度不稳定和EB病毒阳性肿瘤患者客观缓解率分别为85.7%和100%;PD-L1联合阳性评分≥1%者客观缓解率显著高于阴性者(50.0%对0.0%,P<0.001)。治疗6周后ctDNA水平变化可预测缓解与无进展生存。

要点

  • 微卫星高度不稳定和EB病毒阳性转移性胃癌对帕博利珠单抗缓解率极高。
  • PD-L1联合阳性评分≥1%者客观缓解率显著优于阴性者。
  • 治疗6周后ctDNA水平下降与缓解及无进展生存改善相关。

核心结论

  • 微卫星高度不稳定、EB病毒阳性及PD-L1联合阳性评分≥1%与帕博利珠单抗缓解相关,治疗6周后ctDNA变化可预测结局。

研究设计与样本

  • 前瞻性2期临床试验中61例转移性胃癌患者接受帕博利珠单抗挽救治疗,对其组织与循环肿瘤DNA进行分子特征分析。

主要发现

  • 微卫星高度不稳定转移性胃癌客观缓解率为85.7%,EB病毒阳性转移性胃癌客观缓解率为100%,二者互斥。
  • 55例可评估PD-L1联合阳性评分(cut-off≥1%)患者中,PD-L1阳性者客观缓解率为50.0%,阴性者为0.0%,P<0.001。
  • 治疗6周后ctDNA水平变化可预测缓解与无进展生存,ctDNA下降与结局改善相关。

关键数值与推荐

  • 微卫星高度不稳定转移性胃癌客观缓解率85.7%。
  • EB病毒阳性转移性胃癌客观缓解率100%。
  • PD-L1联合阳性评分≥1%者客观缓解率50.0%,阴性者0.0%,P<0.001。

临床怎么用

  • 可将微卫星高度不稳定、EB病毒阳性及PD-L1联合阳性评分≥1%作为筛选可能从PD-1抑制中获益患者的生物标志物。
  • 治疗6周后检测ctDNA水平变化有助于早期预测缓解与无进展生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifying determinants of response, we performed molecular characterization of tissues and circulating tumor DNA (ctDNA) from 61 patients with mGC who were treated with pembrolizumab as salvage treatment in a prospective phase 2 clinical trial. In patients with microsatellite instability-high and Epstein-Barr virus-positive tumors, which are mutually exclusive, dramatic responses to pembrolizumab were observed (overall response rate (ORR) 85.7% in microsatellite instability-high mGC and ORR 100% in Epstein-Barr virus-positive mGC). For the 55 patients for whom programmed death-ligand 1 (PD-L1) combined positive score positivity was available (combined positive score cut-off value ≥1%), ORR was significantly higher in PD-L1(+) gastric cancer when compared to PD-L1(-) tumors (50.0% versus 0.0%, P value <0.001). Changes in ctDNA levels at six weeks post-treatment predicted response and progression-free survival, and decreased ctDNA was associated with improved outcomes. Our findings provide insight into the molecular features associated with response to pembrolizumab in patients with mGC and provide biomarkers potentially relevant for the selection of patients who may derive greater benefit from PD-1 inhibition.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018. PMID: 30013197. doi:10.1038/s41591-018-0101-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。